Current Neuropharmacology

Current Neuropharmacology is a peer-reviewed journal published by Bentham Science Publishers, founded in 2003, presenting reviews and guest-edited issues across neuropharmacology and neuroscience, with a 2025 Journal Impact Factor of 6.1《当代神经药理学》（Current Neuropharmacology）由（Bentham Science Publishers）出版，2003 年创刊，是一份同行评审期刊，以综述与客座编辑专刊的形式覆盖神经药理学与神经科学，2025 年影响因子为 6.1

Scope

• The journal aims to provide current, comprehensive reviews, mini-reviews and guest-edited issues covering all areas of neuropharmacology and related matters of neuroscience期刊旨在提供神经药理学与神经科学相关领域最新、全面的综述、短评与客座编辑专刊
• Reviews cover the molecular, cellular and systems or behavioural aspects of neuropharmacology and neuroscience综述覆盖神经药理学与神经科学的分子、细胞以及系统与行为层面
• The journal serves as a multidisciplinary forum for neuropharmacologists and neuroscientists期刊为神经药理学家与神经科学家提供多学科学术论坛
• Themes include neurodegeneration and neuroinflammation, and the pharmacology of Alzheimer and Parkinson diseases主题包括神经退行与神经炎症，以及阿尔茨海默病与帕金森病的药理学
• Psychopharmacology, including the treatment of major depression and schizophrenia, is regularly addressed精神药理学，包括重度抑郁与精神分裂症的治疗，是常见报道方向
• Pain mechanisms and treatments, and neurotransmitter receptor pharmacology, are within scope疼痛机制与治疗以及神经递质受体药理学均在收录范围之内
• The journal is indexed in Scopus, the Science Citation Index Expanded and MEDLINE through PubMed期刊被（Scopus）、科学引文索引扩展版以及（MEDLINE）与（PubMed）收录

History

• The journal was established in 2003 by Bentham Science Publishers该刊由（Bentham Science Publishers）于 2003 年创办
• Print issues ceased with volume 5, number 4 in December 2007, and the journal has continued online印刷版于 2007 年 12 月第 5 卷第 4 期停出，此后以在线形式连续出版
• It now appears about fourteen times a year, with volume 24 running through 2026现每年约出版 14 期，2026 年为第 24 卷
• Alongside review articles, the journal publishes guest-edited thematic issues on focused topics除综述论文外，期刊还出版围绕具体主题的客座编辑专刊
• Its Journal Impact Factor moved from 7.363 in 2021 through 7.708 in 2022 to 6.1 in 2025, with a 2025 CiteScore of 11.4影响因子由 2021 年的 7.363 经 2022 年的 7.708 变化至 2025 年的 6.1，2025 年 CiteScore 为 11.4
• Page charges of 790 US dollars apply to published research articles, reviews and mini-reviews, and a quick track option is available已发表的研究论文、综述与短评需缴纳 790 美元的版面费，期刊另设快速通道发表选项

Editors

• The Editor-in-Chief is Ferdinando Nicoletti of the Department of Pharmaceutical Sciences at Sapienza University of Rome in Italy现任主编为（Ferdinando Nicoletti），任职于意大利罗马大学药学院
• Thomas E. Salt of the Institute of Ophthalmology, University College London, is Honorary Senior Advisor and a former Editor-in-Chief（Thomas E. Salt）任名誉高级顾问，为期刊前任主编，任职于伦敦大学学院眼科研究所
• Co-editors-in-chief include Vittorio Calabrese and Filippo Caraci of the University of Catania共同主编包括卡塔尼亚大学的（Vittorio Calabrese）与（Filippo Caraci）
• Further co-editors-in-chief are Vittorio Fineschi of Sapienza University of Rome and Giovanni Martinotti共同主编还包括罗马大学的（Vittorio Fineschi）与（Giovanni Martinotti）
• The editorial board includes specialists in neuroscience, imaging and clinical science from Italy and other countries编委会成员包括来自意大利及其他国家的神经科学、影像学与临床科学专家
• The journal publishes comprehensive and mini reviews and guest-edited issues, and manuscripts are submitted through the publisher's online system期刊出版综合性综述、短评与客座编辑专刊，稿件经出版方在线系统提交